Plain-English translation of NCT06638931 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
The ANTARES study is testing a medication called in people with rare, advanced cancers. This is an innovative approach that groups patients with different cancer types together if their tumors share a common feature—the ability to express a protein called PD-L1. The goal is to see if this single medication can work effectively across many different rare cancer types.
Rare cancers are often left behind in medical research because there are so few patients with each type, making it hard to test new treatments. This study was created to break down those barriers and offer hope to people with rare cancers who have run out of other treatment options.
You likely qualify if…
You likely don't qualify if…
You would receive the medication as an intravenous injection (into a vein) once every 4 weeks. Treatment continues for up to 12 months, as long as your cancer is stable or improving and you're tolerating the medication well. Throughout the study, you'll have regular imaging scans and blood tests to monitor how your cancer is responding and to check for any side effects.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Brazil